Abstract
Ximelagatran is a prodrug that is rapidly converted to melagatran, a direct, competitive and reversible inhibitor of the active site of human α-thrombin. Its effect is independent from diet, plasma antithrombin levels, obesity or ethnicity. It has little effect on bleeding time at doses up to twice those required, and interference with other drugs is avoided by the absence of interaction with cytochrome P450. Ximelagatran has been documented in a large clinical programme with proven efficacy in prevention and treatment of venous thromboembolism, prevention of stroke in patients with atrial fibrillation and prevention of major cardiovascular events following a recent myocardial infarction. Bleeding has not been a problem, but increase in liver enzymes is a cause of concern for long term use until more information is available.
Keywords: Antithrombotic agent, thrombosis, coagulation, oral anticoagulant therapy
Letters in Drug Design & Discovery
Title: Ximelagatran: An Oral Direct Thrombin Inhibitor for Anticoagulant Therapy
Volume: 2 Issue: 7
Author(s): Marco L. Rossi, Dennis Zavalloni, Guido Belli and Patrizia Presbitero
Affiliation:
Keywords: Antithrombotic agent, thrombosis, coagulation, oral anticoagulant therapy
Abstract: Ximelagatran is a prodrug that is rapidly converted to melagatran, a direct, competitive and reversible inhibitor of the active site of human α-thrombin. Its effect is independent from diet, plasma antithrombin levels, obesity or ethnicity. It has little effect on bleeding time at doses up to twice those required, and interference with other drugs is avoided by the absence of interaction with cytochrome P450. Ximelagatran has been documented in a large clinical programme with proven efficacy in prevention and treatment of venous thromboembolism, prevention of stroke in patients with atrial fibrillation and prevention of major cardiovascular events following a recent myocardial infarction. Bleeding has not been a problem, but increase in liver enzymes is a cause of concern for long term use until more information is available.
Export Options
About this article
Cite this article as:
Rossi L. Marco, Zavalloni Dennis, Belli Guido and Presbitero Patrizia, Ximelagatran: An Oral Direct Thrombin Inhibitor for Anticoagulant Therapy, Letters in Drug Design & Discovery 2005; 2 (7) . https://dx.doi.org/10.2174/157018005774479168
DOI https://dx.doi.org/10.2174/157018005774479168 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Mechanism Aspect of ER Stress in Alzheimer's Disease: Current Approaches and Future Strategies
Current Drug Targets Anti-Angiogenic Therapies for Children with Cancer
Current Cancer Drug Targets Hydrogen Gas as an Exotic Performance-Enhancing Agent: Challenges and Opportunities
Current Pharmaceutical Design Herbal Drug use in Sickle Cell Disease Management; Trends and Perspectives in Sub-Saharan Africa - A Systematic Review
Current Drug Discovery Technologies Hypoxia as an Initiator of Neuroinflammation: Microglial Connections
Current Neuropharmacology A Novel Nomogram for Predicting Prognosis after Mechanical Thrombectomy in Patients with Acute Ischemic Stroke
Current Neurovascular Research Emerging Roles of microRNAs in the Molecular Responses to Hypoxia
Current Pharmaceutical Design One-Compound-Multi-Target: Combination Prospect of Natural Compounds with Thrombolytic Therapy in Acute Ischemic Stroke
Current Neuropharmacology Nanowired Drug Delivery to Enhance Neuroprotection in Spinal Cord Injury
CNS & Neurological Disorders - Drug Targets Molecular Docking Studies Applied to a Dataset of Cruzain Inhibitors
Current Computer-Aided Drug Design Trends in Nanotechnology Patents Applied to the Health Sector
Recent Patents on Nanotechnology Immune Endocrinological Evaluation in Patients with Severe Vascular Acquired Brain Injuries: Therapeutical Approaches
Endocrine, Metabolic & Immune Disorders - Drug Targets The Clinical Problems of Hypertension Treatment in Hemodialysis Patients
Current Vascular Pharmacology Leech Thrombin Inhibitors
Current Pharmaceutical Design Liraglutide Therapy in a Prediabetic State: Rethinking the Evidence
Current Diabetes Reviews Protein Aggregation and Self Assembly in Health and Disease
Current Proteomics fMRI Simulator Training to Suppress Head Motion
Neuroscience and Biomedical Engineering (Discontinued) Prevalence of Pre-Existing Risk Factors for Adverse Events Associated with Atypical Antipsychotics Among Commercially Insured and Medicaid Insured Patients Newly Initiating Atypical Antipsychotics
Current Drug Safety Nonalcoholic Fatty Liver Disease vs. Nonalcoholic Steatohepatitis: Pathological and Clinical Implications
Current Vascular Pharmacology Nanostructured Lipid Carriers (NLCs) for Drug Delivery: Role of Liquid Lipid (Oil)
Current Drug Delivery